Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated

Latest Peripheral Arterial Disease Articles

Peripheral Arterial Disease Archives
Print | Email | Share | Comments (1)

Diabetes Patients on Insulin Sensitizers Run Lower PAD Risk


Jul 5, 2013

How PAD affects leg arteries

Insulin sensitizers--drugs that increase sensitivity to insulin such as Avandia and Actos--could help lessen the risk of peripheral arterial disease (PAD) for those with type 2 diabetes, according to a new study.

That's great news for the 8 million Americans who are currently battling PAD, a disease that causes narrowing of the arteries, leading to decreased blood flow to the legs. It leads to pain, tingling and a slower rate of healing for wounds. Symptoms of the disease include pain after walking long distances, a shiny appearance to the skin on your legs, coldness or numbness of the legs and feet, and trouble walking.

The study, which appeared in the American Diabetes Association journal Diabetes Care, looked at 1,479 patients with type 2 diabetes.

Of those participants, 24.1 percent of those who received insulin through medication developed PAD, compared to a rate of 16.9 percent for those taking insulin-sensitizing drugs.

Those taking insulin-sensitizing drugs also showed a reduced rate of amputation, according to the study. Statistics from the American Diabetes Association show that 60 percent of all lower-leg amputations are diabetes-related.

"Our results suggest that treatment of type 2 diabetic patients with insulin sensitizers might reduce the morbidity and treatment cost of PAD in this population," the researchers concluded.

"From a broader physiological perspective, our results also point to the possibility that treatment with insulin-sensitizing medications may slow the progression of systemic atherosclerosis in this population, at least when compared to treatment with insulin-providing medications," Dr. Andrew D. Althouse said in an e-mail interview with Reuters Health.


Categories: Actos, Artherosclerosis, Avandia, Insulin Sensitizers, Peripheral Arterial Disease



You May Also Be Interested In...


Click Here To View Or Post Comments

Comments 1 comment - Jul 5, 2013

©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.